StreetAlpha.app
Home › Stocks › SANA

Sana Biotechnology, Inc. (SANA)

Healthcare
$1.88
▲ +0.00%
LAST CLOSE · NOV 17

Sana Biotechnology develops engineered cell therapies for type 1 diabetes and B cell diseases, based in Seattle. It last closed at $1.88 on Nov 17, up 0.00% on the day. The average 12-month price target from 2 analysts is $12.00 (+538.3% from the last close), with a high of $13.00 and a low of $11.00. In the past 30 days there were 1 dark pool print totaling $120K, the largest $120K.

AI Auto Pilots
Is SANA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$149.3M
EPS (diluted)
−$0.52
Free cash flow
−$145.1M
Valuation
Market cap
$563.3M
299.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.1M
At Sep 30
Shareholder equity
$180.4M
Shares outstanding
299.6M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$355.9M−$355.9MFY2021FY2022: −$269.5M−$269.5MFY2022FY2023: −$283.3M−$283.3MFY2023FY2024: −$266.8M−$266.8MFY2024FY2025: −$244.2M−$244.2MFY2025

From SANA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated SANA in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 538.3% upside

Based on 2 analysts who set a price target on SANA in the past 90 days. The average target is $12.00, with a high of $13.00 and a low of $11.00, compared with the last close of $1.88.

Low $11.00Avg $12.00High $13.00
Blue marker: last close $1.88
Highest target$13.00
Average target$12.00
Lowest target$11.00
Latest rating changes
CitigroupMaintained
Nov 16Buy$11
Morgan StanleyMaintained
Nov 16Buy$13
B of A SecuritiesMaintained
Aug 14Buy$6
DateFirmActionRatingPrice target
Nov 16CitigroupMaintainedBuy$11
Nov 16Morgan StanleyMaintainedBuy$13
Aug 14B of A SecuritiesMaintainedBuy$6
Loading…

Technical Analysis

SANA · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 25% below its 20 day and 41% below its 50 day average. It is 73% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $1.84, and the nearest resistance the Pivot R1 at $1.91.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 9.6%/day
Key levels
$5.4952 week high+192.0%
$3.25200 day average+72.9%
$3.13100 day average+66.5%
$2.77Swing high (Oct 29)+47.3%
$2.6550 day average+41.0%
$2.3420 day average+24.5%
$1.91Pivot R1+1.6%
$1.88Pivot+0.0%
$1.88Last close
$1.8452 week low−2.1%
$1.84Pivot S1−2.1%
Indicators
RSI (14)29.87Oversold below 30Oversold
MACD-0.19Below its signal lineBearish
Stochastic7.5Near the bottom of its rangeOversold
ADX (14)26.2Trending down
Williams %R-96.2Oversold below −80, overbought above −20Oversold
CCI (20)-200.3Oversold below −100, overbought above 100Oversold
Rate of change−22.9%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SANA

What happened before

See how SANA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SANA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SANA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SANA in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$120K
Largest print
$120K
Loading…

SANA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼79 buying vs 101 selling
  • ▲Held by funds +14.9 pts
  • ▼Funds holding -9
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding202211−4.3%
In funds' top 1043+33.3%
Held by funds76.6%61.7%+14.9 pts
New / increased23 / 5631 / 68−20.2%
Reduced / sold out71 / 3061 / 23+20.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SANA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SANA is in one of them and how their past SANA trades turned out.

SANA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SANA in an article yet. Here's the latest on the wider market.

About Sana Biotechnology

Sana Biotechnology is a biotechnology company based in Seattle, Washington, that develops engineered cell therapies. Its lead candidate, SC451, is meant to treat type 1 diabetes with cells that can be transplanted without immunosuppression. Its in vivo CAR T candidate, SG293, is being developed for B cell cancers and B cell mediated autoimmune diseases. The company's products are still in development and are aimed at patients with these conditions.

Headquarters
Seattle, WA